Latest News about GILD
Recent news which mentions GILD
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
August 16, 2024
From Benzinga
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
From Benzinga
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
August 15, 2024
Tickers
GILD
From Benzinga
7 Defensive Stocks to Buy as Investors Seek Shelter
August 14, 2024
From InvestorPlace
3 Stocks Retirees Should Absolutely Love
August 10, 2024
From Motley Fool
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
August 09, 2024
From Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
August 09, 2024
From Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
August 08, 2024
Tickers
GILD
From Motley Fool
Tickers
GILD
From InvestorPlace
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
August 08, 2024
From Benzinga
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
August 08, 2024
From Benzinga
From Benzinga
From Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
August 02, 2024
From InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 02, 2024
From Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
July 31, 2024
From InvestorPlace
From InvestorPlace
From Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
July 29, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 26, 2024
From Benzinga
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On
July 25, 2024
From Benzinga
From Motley Fool
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
July 24, 2024
From Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
From Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.